MiRNAs are emerging as important epigenetic modulators of multiple target genes, leading to abnormal cellular signaling involving cellular proliferation in cancers. Aberrant miRNA expression has been observed in human glioblastoma (GBM). The present study was to evaluate the expression and molecular mechanisms of COX-2 and miR-26b in human GBM tissues and GBM cell lines T98G, U87 and U251. In the present study, we found that expression of miR-26b was markedly downregulated in GBM cell lines and human GBM tissues, compared to matched non-tumor associated tissues. Furthermore, miR-26b expression was inversely proportional to that of COX-2 mRNA and protein. Ectopic expression of miR-26b dramatically reduced the proliferation, colony formation, and proliferation/apoptosis-related proteins in GBM cells. Flow cytometry analysis showed that ectopic expression of miR-26b significantly decreased the percentage of S phase cells and increased the percentage of G1/G0 phase cells. Finally, luciferase reporter assay revealed that miR-26b inhibited the expression of COX-2 by binding to the 3'-UTR of COX-2 in GBM cells. Taken together, our results suggest that miR-26b plays an important role to inhibit the proliferation and invasion of GBM cells, and presents a novel mechanism for direct miR-26b-mediated suppression of COX-2 in GBM. Thus, miR-26b/COX-2 may have an important role in treatment of GBM patients.
INTRODUCTION
Gliomas have been reported as the most common one of primary cerebral tumors in central neural system. According to the regulation of World Health Organization (WHO) classification stantard, all gliomas can be divided into 4 grades on the basis of their histology [1] [2] . Although some latest therapy technologies (resection and radio-/chemotherapy) have been introduced into the treatment of gliomas, the whole effects on patients with gliomas remain to be not satisfactory [3] [4] . The glioblastoma multiforme (GBM) acts as grade IV glioma, and has the most common and malignant properties [5] [6] . Due to the unsatisfactory survival status of patients with GBM, thus it is essential to hunt for some new and useful biomarker, which can be applied into diagnosis and treatment.
MicroRNAs act as a kind of small and non-coding RNAs with the length of about 20 nucleotides, and take part in the regulation of gene expression. Mechanically, miRNAs can bind the 3'-unstranslated regions (3'-UTR) of the related target mRNA sequences, and then suppresses gene transcription or facilitate the degradation of mRNA [7, 8] . To date, miRNAs have been demonstrated to play important roles in a wide range of oncogenic activities, including proliferation, apoptosis, angiogenesis, and metastasis [9] [10] [11] [12] . Although the miRNA-induced potential regulation mechanisms are still under investigation, some current reports have indicated that the expression model of miRNA will be useful for the diagnosis and prognosis of human tumors. Notably, it has been reported that miR-26b has a wide role in regulation of some functions involving suppression of cancer cell proliferation and inhibition of organ metastasis of different cancers. At the same time, the expression of miR-26b was found to be downregulated in some cancers, inducing chronic myelogenous leukemia, gastric cancer, and colorectal carcinoma [13] [14] [15] . However, little is known about the role of miR-26b in the development of GBM.
In the present study, we demonstrated that the expression of miR-26b was extremely down-regulated in GBM cells and samples; however its expression was not changed in their own adjacent non-tumor samples. Using in-vitro assay, we found that miR-26b regulates GBM cell proliferation by directly targeting 3'-UTRs of COX-2, and the over-expression of miR-26b altered the proliferative and invasive property. Our findings indicated that the inhibited miR-26b expression can enhance the proliferation and invasion of GBM cells.
RESULTS

The expression of COX-2 in GBM tissues and lines
To well understand the mechanisms underlying miR-26b-induced tumor biology and miR-26b-COX-2 pathway, we firstly detected the expression model and status of COX-2 in human GBM tissues using the realtime RT-PCR and western blot. Our findings showed that the expression of COX-2 mRNA was significantly up-regulated in cancer tissues, however, the expression was not changed in their own adjacent non-tumor tissues (p<0.001) (Figure 1a ). In addition, results from western blot analysis revealed that the expression of COX-2 protein was also significantly up-regulated in cancer tissues, however, the expression was not changed in their own adjacent non-tumor tissues (p<0.001) (Figure 1b) . Next we further detected the expression model and status of COX-2 in GBM cell lines, including T98G, U87 and U251. All cells were subjected to the real-time RT-PCR and western blot. Our findings showed that the expression of COX-2 mRNA and protein were indeed obviously higher as compared with their own adjacent non-tumor tissues (all p<0.001) (Figure 2a, 2b) .
The expression of miR-26b in GBM tissues and cell lines
To well understand the mechanisms underlying miR-26b-induced tumor biology and miR-26b-COX-2 pathway, we secondly detected the expression model and status of miR-26b in human GBM tissues using the real-time RT-PCR. Real-time RT-PCR analyses revealed that the expression of miR-26b was significantly downregulated in representative GBM tissues, and GBM cell lines including T98G, U87 and U251. However, the expression was not changed in their own adjacent nontumor tissues (all p<0.001) (Figure 3a) . To identify whether the downregulation of miR-26b can be found in all GBM of human GBM tissues. Quantification analysis was defined as the relative density of COX-2 mRNA to GAPDH. GAPDH was used as an internal control. Results shown are the mean ± SEM of repeated independent experiments. *p<0.001, compared with control, one-way ANOVA. b. The expression of COX-2 protein was examined in 30 pairs of human GBM tissues using western blot. The average COX-2 protein expression was normalized to β-actin. Results shown are the mean ± SEM of repeated independent experiments. *p<0.001, compared with control, one-way ANOVA. www.impactjournals.com/oncotarget representative GBM tissues and cell lines, including T98G, U87 and U251. Quantification analysis was defined as the relative density of COX-2 mRNA to GAPDH at each time point. GAPDH was used as an internal control. Results shown are the mean ± SEM of repeated independent experiments. *p<0.001, compared with control, one-way ANOVA. b. The expression of COX-2 protein was examined in representative GBM tissues and cell lines, including T98G, U87 and U251 using western blot. The average COX-2 expression was normalized to β-actin expression. Results shown are the mean ± SEM of repeated independent experiments. *p<0.001, compared with control, one-way ANOVA. tissues, we also detected the expression of miR-26b in all 30 GBM tissues and their own adjacent non-tumor tissues. As shown in Figure 3b , our findings showed that the expression of miR-26b was significantly reduced in all GBM tumor tissues. However, the expression was not changed in their own adjacent non-tumor tissues (all p<0.001). Taken together, our findings indicated that the expression of miR26b is decreased in the development of GBM.
miR-26b expression is inversely proportional to COX-2 expression
To elucidate the biological relationship between miR-26b and COX-2 in cancer tissues of GBM, we analyzed the correlation between miR-26b and COX-2 mRNA, and COX-2 protein. As shown in Figure 4 , the linear regression analysis revealed that the miR-26b expression was negatively associated with the expression of COX-2 mRNA in 30 cases of GBM specimens (p=0.001) ( Figure 4a ). As expected, miR-26b expression was also negatively associated with the expression of COX-2 protein in 30 cases of GBM specimens (p=0.012) (Figure 4b ).
miR-26b inhibits proliferation and invasion of GBM cells
To explore the role of miR-26b in the biological progression of GBM, we firstly explored the effect of miR-26b mimics on the overexpression of miR-26b in U87 and U251 cells, and confirmed that miR-26b mimics enhanced the expression of miR-26b (Figure 5a, 5b) . Afterwards, we examined proliferation and invasion of GBM cells with different treatment. MTT assay revealed that U87 and U251 cells with miR-26b overexpression had obviously lower growth rate, however the growth rate of control cells was not changed (Figure 5c, 5d) . Besides, we also observed that the ectopic expression of miR-26b extremely decreased the invasion capacity of U87 and U251 cells (Figure 6a ), which was indicated based on reduced colony numbers and sizes. These findings indicate that miR-26b overexpression inhibits cell proliferation and cell invasion in the development of GBM. As expected, flow cytometry analysis revealed that ectopic miR-26b expression obviously reduced the percentage of U87 and U251 cells in the S and G2/M stage, at the same time, ectopic miR-26b expression increased the percentage of U87 and U251 cells in the G1/G0 stage (Figure 6b ), indicating that miR-26b overexpression indeed inhibits the proliferation of GBM cells by inducing cell cycle arrest. Notably, the expression of Bcl-2 and cyclin D1 was also significantly reduced but the expression of Bax was obviously increased in U87 and U251 cells transfected with miR-26b mimics (Figure 6c ).
COX-2 is a direct target of miR-26b
According to recent studies, we used putative miRNA analysis software or website (TargetScan, Pictar, miRANDA) to demonstrate that COX-2 may be a potential target for miR-26b. In view of prediction results, our western blot analysis revealed that miR-26b mimics decreased the expression of COX-2 protein in U87 and U251 cells (Figure 6c ), suggesting the inhibition effects of miR-26b on cell proliferation probably via targeting the expression of COX-2. Using COX-2 mutation, we found that ectopic miR-26b expression indeed decreased the expression of COX-2 in cells transfected with 3'UTR-WT of COX-2, however the expression of COX-2 in cells transfected with 3'UTR- MUT of COX-2 was not altered, which suggested that miR-26b affected the expression of COX-2 by binding the 3'UTR of COX-2 (Figure 7a, 7b) . Besides, we also observed that overexpression of miR-26b could decrease the luciferase activity of COX-2-3'UTR-WT in a consistent and dose-dependent fashion, rather than the luciferase activity of COX-2-3'UTR-MUT ( Figure  7c, 7d) , which indicated that COX-2 was a direct target of miR-26b.
DISCUSSION
MicroRNAs have been reported as a kind of small RNA sequence that affect the transcription expression of some related mRNA or gene by binding specific sequences of mRNA. To date, miRNAs have been demonstrated as a useful regulator in the development of some tumors, including cell growth, apoptosis, differentiation, invasiveness and migration, and usually serve as a kind of tumor suppressors [7] [8] [9] [10] [11] . It has been reported that the COX-2 expression can be found to be increased in a wide variety of tumors, such as human colorectal cancer, liver cancer, cervical cancer, and pancreatic cancer [16] [17] [18] [19] . Some studies indicated that the expression of COX-2 has been thought as a useful tumor biomarker, and COX-2 exhibited the increased invasion potential in cancers. In the present study, we investigated the expression model and molecular role of miR-26b and COX-2 in human GBM tissues and cells.
In this work, we demonstrate that the expression of COX-2 mRNA was obviously changed in human GBM cell lines and samples as compared to their adjacent nontumor tissues. The expression of COX-2 protein was also altered in human GBM cell lines and samples as compared with their adjacent non-tumor samples. Most importantly, the linear regression analysis revealed that the expression of miR-26b was negatively related with the expression of COX-2 mRNA or protein. Consistent with recently published articles, the expression of miR26b might be recommended as a tumor suppressor in breast cancer, which could act as a prognosis biomarker and a treatment target for breast cancer patients [20] . These findings suggested that miR-26b/COX-2 pathway is indeed involved in the development of GBM.
Furthermore, the overexpression of miR-26b reduced GBM cell proliferation and cell cycle progression, indicating that in-vivo overexpression of miR-26b may serve as a tumor suppressor, thus downregulation of miR-26b will facilitate the biological progression of GBM. Consistent with our study, it has been reported that miR-26b can also affect cell growth and invasiveness of colorectal cancer, but the inhibition effect of miR-26b can be partially attenuated by the enhancement of the target expression [21] . Some studies also found that miR-26b is able to inhibit the NF-κB signaling, and affects the expression of TAK1 and TAB3, which further sensitizes the doxorubicin-induced liver cancer cell apoptosis [22] . Another report also indicated that the expression of miR-26 can activate the pRb protein, and then block the G1/S-phase transition [23] . Overall, our study offered the latest evidence that the expression of miR-26b is significantly under expressed and exerts its anti-tumor role in the development of GBM by directly affecting the transcription of COX-2.
Notably, it has been reported that COX-2 inhibitors have the capacity of enhancing the sensitivity of tumors to radia-/chemotherapy based on some animal model experiments. For example, the recent study identified that administration with COX-2 inhibitor E-6087 could promote and facilitate apoptosis response of gliomas to the radiation intervention in mice models. At the same time, the radiation treatment combined with COX-2 inhibitor E-6087 not only promoted cell apoptosis, bur also affected the formation of murine microvascular systems [24, 25] . In addition, in vitro also identified that the antitumor effect of radiation treatment on murine intracranial glioma growth is enhanced by the inhibition of COX-2 [26, 27] . Thus, it is plausible that up-regulated miR-26b may sensitize GBM to chemotherapy-induced apoptosis by inhibiting the expression of COX-2.
In summary, in the present study, a new important role of miR-26b was identified, and miR-26b was demonstrated to regulate the tumorigenicity of GBM. The aberrant expression of miR-26b was associated with the proliferation and invasion of GBM. In addition to these findings, we also further ensured that miR26b binds the 3'-UTR of the COX-2 mRNA, and then reduced the expression level of COX-2. Our findings will provide a new insight for the treatment of GBM patients.
MATERIALS AND METHODS
Ethical statement
For the use of clinical materials for research purposes, samples were obtained with prior written informed consents from the patients and approval from the Institutional Research Ethical Committees of Yidu Central Hospital, Weifang Medical University.
Cell culture and tissues
Human GBM cell lines T98G, U87 and U251 were purchased from American Type Culture Collection (Manassas, VA). All cells were cultured in DMEM, 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA) at 37°C in a humidified atmosphere under 5% CO2. In this study, 30 GBM samples were randomly chosen from the Department of Pathology in Shandong Cancer Hospital and Yidu Central Hospital of Weifang Medical University from January 2011 to June 2014. All samples were fixed with 10% formaldehyde and embedded with paraffin. Informed consent was obtained from all of the patients.
COX-2 3'-UTR and miR-26b mimics construct
COX-2 3'-UTR constructs were PCR amplified using cDNA encoding COX-2 as templates, and subcloned into pGL3-basic vector for luciferase reporter assay. PCR with Quickchange site directed mutagenesis kit from Qiagen (USA) were used for construction of mutant COX-2 3'-UTR. The miRNA mimics (ago-miR-26b), and negative controls of miR-26b, purchased from RiboBio (Ribo-Bio, Guangzhou, China) were transfected at final concentration of 40 nM. The FuGENE HD transfection agent (Promega, USA) was used according to the manufacturer's instructions.
Quantitative real-time RT-PCR analysis
Total RNA was isolated by using TRIzol (Invitrogen, USA). The concentration and quality of each RNA sample was determined using the A260/A280 spectrophotometric reading. The cDNA was synthesized with TaqMan reverse transcription reagents (Applied Biosystems, Branchbury, NJ, USA), following the manufacturer's recommendations. Real-time PCR was carried out using 7500 fast Real-time PCR System (Applied Biosystems). Reactions were run in three independent experiments. The relative fold changes in mRNA and miR-26b expression were calculated using the 2−ΔΔCt method. Besides the relative expression was also normalized to GAPDH. The primer sequences were shown.
COX RT-PCR for miR-26b was performed using real-time PCR Universal Reagent (GenePharma). U6 was used as an internal control.
Western blot analysis
Protein was extracted from cells using 1×radioimmunoprecipitation assay lysis buffer (Santa Cruz Biotechnology), subjected to SDS-PAGE, transferred to polyvinylidene difluoride membrane. Membranes were blocked for 2 hour in 5% skimmed milk and probed with antibody against human COX-2, Bcl-2, Bax and cyclin D1 (Abcam, Cambridge, UK, 1:1000 dilution) or β-actin (Santa Cruz Biotech, Santa Cruz, CA, 1:1000 dilution) overnight at 4°C, and then with peroxidase-conjugated secondary antibody (Santa Cruz Biotech, Santa Cruz, CA, 1:1000 dilution), visualized by chemiluminescence (GE, Fairfield, CT, USA).
Luciferase assays
Cells were seeded in triplicate in 24-well plates and allowed to settle for 24 h. 100 ng of pGL3-COX-2-3'UTR (wt/mut) or control-luciferase plasmid plus 1 ng pRL-TK renilla plasmid (Promega, Madison, WI) were transfected into cells using Lipofectamine 2000 (Invitrogen Co., Carlsbad, CA) according to the manufacturer's recommendations. Luciferase and renilla signals were measured 48 h after transfection using the Dual Luciferase Reporter Assay Kit (Promega, Madison, WI) according to the manufacturer's protocol. Three independent experiments were performed and the data are presented as the mean ± SEM.
Flow cytometry analysis
Cells were harvested by trypsinization, washed in ice-cold PBS, and fixed in 80% ice-cold ethanol in PBS. Before staining, cells were sedimented in a chilled centrifuge and resuspended in cold PBS. Bovine pancreatic RNase (Sigma-Aldrich) was added to a final concentration of 2 mg/ml, and cells were incubated at 37°C for 30 min, followed by incubation with 20 mg/ml of propidium iodide (Sigma-Aldrich) for 20 min at room temperature. Cell cycle profiles of cells were analyzed using a FAGBMC alibur flow cytometer (BD Biosciences).
3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT)
Cells, seeded on 96-well plates, were stained at indicated time points with 100 ml sterile MTT dye (0.5 mg/ml, Sigma) for 4 h at 37°C, followed by removal of the culture medium and addition of 150 ml of dimethyl sulphoxide (DMSO) (Sigma, St. Louis, MO, USA). The absorbance was measured at 570 nm, with 655 nm as the reference wave length. All experiments were performed in triplicate.
Invasion assay
For invasion assay, cells were added to the upper well chamber and coated with Matrigel (BD Biosciences) for 24 hours. Then, cells on the upper membrane surface were removed by careful wiping with a cotton swab, and the filters were fixed with 95% ethanol and stained with 0.2% crystal violet solution (Sigma) and then counted.
Statistical analysis
Statistical analyses were carried using the SPSS 17.0 program. An independent samples test was run to analyze the significance of the differences found. P-values less than 0.05 were considered to be statistically significant. All data are presented as the mean ± SEM.
